I understand your concern, however I believe the blue sky potential is more aligned (medically) with 2591 than Trof. For many years now Neuren have been very positive about both these drugs, but IMO even moreso with 2591.
I feel the potential for Trof has been realised, with no other major avenues of treatment to pursue - however the story of 2591 is just beginning - both medically and financially.
Ann: Q2 2023 quarterly activity and cash flow report, page-15
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.01 |
Change
-0.010(0.08%) |
Mkt cap ! $1.662B | |||
| Open | High | Low | Value | Volume |
| $13.06 | $13.26 | $12.81 | $5.865M | 451.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14541 | $13.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.02 | 2438 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |